Findings provide a unifying framework for genomic heterogeneity in EAC, uncover underappreciated tumor suppressor pathways, and establish a resource to guide mechanistic and translational studies aimed at improving treatment strategies in this aggressive cancer.
Abstract
Esophageal adenocarcinoma (EAC) is a genetically heterogeneous malignancy with few recurrent drivers, limiting effective targeted therapies. Although EAC arises from Barrett’s esophagus (BE), mechanisms driving progression from this premalignant state to invasive cancer remain unclear. We combined pooled CRISPR-Cas9 loss-of-function screening, in vivo tumorigenicity assays, and Perturb-seq profiling to define functional drivers of BE transformation. We identified 37 tumor suppressors whose loss promotes progression to EAC, defining a functional landscape of tumor initiation. Despite genetic diversity, these losses converged on four transcriptional programs involving metabolic reprogramming, cell cycle progression, RNA processing, and cellular motility. Furthermore, we identify loss of NIPBL, TGFBR2, and RPL22 as key mediators of resistance to platinum- and taxane-based chemotherapy. Collectively, these findings provide a unifying framework for genomic heterogeneity in EAC, uncover underappreciated tumor suppressor pathways, and establish a resource to guide mechanistic and translational studies aimed at improving treatment strategies in this aggressive cancer.
An unbiased in vivo genome-wide CRISPR/Cas9 loss-of-function screen in a breast cancer xenograft model uncovers clinically relevant metastasis suppressor genes (MSGs), including VPS45, CMTR2, RBSN, and NF2, whose loss enhances lung colonization.
Soaad Galal, Leslie Chaltel Lima, Ni Wang et al.· Nature Communications· 0 citations
It is demonstrated for the first time that LOY is significantly enriched in advanced-stage disease and the aggressive basal molecular subtype, establishing LOY as a causal genetic driver of PDAC progression, acting through epigenetic remodeling to promote EMT, basal subtype identity, metastasis, and therapy resistance.
M. Dorsch, Felix E. G. Beaudry, A. Baginska et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest malignancies, with poor survival largely driven by late-stage diagnosis. Approximately 85% of patients present with advanced disease, limiting curative treatment options. A major challenge in PDAC is the absence of biomarkers capable of identify...
Paula D. Santos, Lisa Young, Sarah Baloul et al.· Cancer Research· 0 citations
The recent approval of covalent KRAS G12C inhibitors, sotorasib and adagrasib, has revealed that targeted KRAS blockade can remodel the TME toward an immunostimulatory state, providing a mechanistic rationale for combining KRAS-directed agents with immune checkpoint blockade, STING agonists, and neoantigen vaccines.
Vasudevan Ramachandran, H. L. Koyou, Siddarth Raajasekar et al.· Frontiers in Oncology· 0 citations
This work modeled resistance using patient-derived xenografts from two PDACs harboring pathogenic germline BRCA2 variants, and identified convergent transcriptional and epigenetic cell states associated with BRCA2-reversion-independent platinum/PARPi resistance in PDAC.
J. Romero, Yi-Fan Wang, Edward Shanbedi et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited therapeutic options. Approximately one-third of PDAC tumors harbor alterations in chromatin-remodeling genes, including loss-of-function mutations in ARID1A occurring in approximately 8% of cases. However, actionable vulnerabilities...
Wen-Jia Wang, Olivia Schmidt, S. Blick-Nitko et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.